 Other antiangiogenic agents have been studied in GBM patients Sathornsumetee 2009, Van Meir 2010, Wick 2011, with encouraging results but still insufficient when used as single agents. Among them, pazopanib is thought to be promising. It is an orally tyrosine kinase inhibitor with potently inhibition of VEGFR-1, -2, -3, c-kit and PDGFR-α, -β Castaneda 2009, Schutz 2011. Interestingly, these 2 PDGFR subtypes are overexpressed in malignant gliomas Verhaak 2010. Furthermore, pazopanib is already validated in patients with advanced renal cell carcinoma and soft-tissue sarcomas Sleijfer 2009, Sternberg 2010. 